LGP Cannatrek Merger Creates Global Medicinal Cannabis Platform with Integration Progress Underway
Little Green Pharma Ltd (ASX: LGP) completed its merger with Cannatrek Ltd on 1 June 2026, establishing one of the world's largest pure-play medicinal cannabis businesses with vertically integrated operations across Australia and Europe. During the June quarter, the combined group identified approximately AU$3 million in targeted cost synergies across manufacturing, cultivation, procurement and corporate functions while reporting a net increase of around AU$3 million in cash and cash equivalents. The company generated AU$1.8 million in net operating cash flow from customer receipts of AU$22.9 million and ended the quarter with AU$20.6 million in cash alongside AU$9.2 million in undrawn financing facilities. Management has commenced investments to accelerate expansion across the UK and Germany, including optimisation of its Denmark manufacturing facility, while progressing integration initiatives aimed at strengthening operational efficiency, enhancing product portfolios and supporting long-term international growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
LGP Cannatrek Merger Creates Global Medicinal Cannabis Platform with Integration Progress Underway
Little Green Pharma Ltd (ASX: LGP) completed its merger with Cannatrek Ltd on 1 June 2026, establishing one of the world's largest pure-play medicinal cannabis businesses with vertically integrated operations across Australia and Europe. During the June quarter, the combined group identified approximately AU$3 million in targeted cost synergies across manufacturing, cultivation, procurement and corporate functions while reporting a net increase of around AU$3 million in cash and cash equivalents. The company generated AU$1.8 million in net operating cash flow from customer receipts of AU$22.9 million and ended the quarter with AU$20.6 million in cash alongside AU$9.2 million in undrawn financing facilities. Management has commenced investments to accelerate expansion across the UK and Germany, including optimisation of its Denmark manufacturing facility, while progressing integration initiatives aimed at strengthening operational efficiency, enhancing product portfolios and supporting long-term international growth.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au